Lifevantage (LFVN) reported $229M in revenue for fiscal 2025, +14.2% year on year. That ranks #2617 by revenue among 2853 SEC filers and #275 in Healthcare. Net income was $9.8M, a net margin of 4.3%. Revenue has grown 0.8% a year on average since 2013 ($208M then). The fiscal 2025 balance sheet shows $61.2M in total assets, $10.2M in cash and $2.4M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $229M | +14.2% | FY20252025-06-30 |
| Gross profitGrossProfit | $184M | +15.7% | FY20252025-06-30 |
| Operating incomeOperatingIncomeLoss | $12.2M | +181.6% | FY20252025-06-30 |
| Net incomeNetIncomeLoss | $9.8M | +233.8% | FY20252025-06-30 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $11.9M | −2.6% | FY20252025-06-30 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $1.4M | −38.9% | FY20252025-06-30 |
| Total assetsAssets | $61.2M | −10.7% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $33.0M | +10.4% | FY20252025-12-31 |
| CashCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $10.2M | −52.9% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $2.4M | −45.5% | FY20182018-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $43.7M | $1.4M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Lifevantage Corp
- Ticker
- LFVN
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 06-30
- CIK
- 0000849146
Filings
- 10-KAug 27, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-QFeb 4, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| AnaptysbioANAB | $235M | −$13.2M |
| CerusCERS | $234M | −$15.6M |
| TalkspaceTALK | $229M | $7.8M |
| LifevantageLFVN | $229M | $9.8M |
| Puma BiotechnologyPBYI | $228M | $31.1M |
| AxogenAXGN | $225M | −$15.7M |
| Ideaya BiosciencesIDYA | $219M | −$114M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Lifevantage — Key figures |url=https://companiesranked.com/en/company/lifevantage |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Lifevantage — Key figures. CompaniesRanked. https://companiesranked.com/en/company/lifevantageBibTeX
@misc{companiesranked-en-company-lifevantage-2026,
author = {{CompaniesRanked}},
title = {{Lifevantage — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/lifevantage}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-371257 · August 27, 2026
{{cite web |title=Lifevantage — Key figures — 10-K (0001193125-26-371257) |url=https://www.sec.gov/Archives/edgar/data/849146/000119312526371257/lfvn-20260630.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-08-27}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.